The population density of Massachusetts was 876 in 2018. The population density of New Jersey was 1,208 in 2018.
Population Density
Population Density is computed by dividing the total population by Land Area Per Square Mile.
Above charts are based on data from the U.S. Census American Community Survey | ODN Dataset | API -
Geographic and Population Datasets Involving Massachusetts or New Jersey
- API
HIV/AIDS transmission rate among adults and adolescents, New Jersey, by year: Beginning 2010
healthdata.nj.gov | Last Updated 2020-09-30T14:26:53.000ZRate: Number of new cases of HIV/AIDS infections per 100,000 population. Definition: The rate of HIV transmission among adolescents and adults age 13+ per 100,000 population. Data Source: New Jersey Enhanced HIV/AIDS Reporting System (eHARS) Division of HIV/AIDS, STD, and TB Services, New Jersey Department of Health
- API
Diabetes death rate (per 100,000), New Jersey, by year: Beginning 2010
healthdata.nj.gov | Last Updated 2020-12-09T18:52:42.000ZRate: Age-adjusted death rate, number of deaths due to diabetes, per 100,000 population. Definition: Deaths with diabetes as the underlying cause of death (ICD-10 codes: E10-E14). Data Sources: (1) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health (2) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development
- API
Breast Cancer Death Rate (per 100,000 females), New Jersey, by year: Beginning 2010
healthdata.nj.gov | Last Updated 2020-12-08T19:55:33.000ZRate: Number of deaths among females due to breast cancer per 100,000 female population. Definition: Number of deaths per 100,000 with malignant neoplasm (cancer) of the female breast as the underlying cause (ICD-10 codes: C33-C34). Data Sources: (1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html (2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health (3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development
- API
Bronx Zip Population and Density
bronx.lehman.cuny.edu | Last Updated 2012-10-21T14:06:17.000Z2010 Census Data on population, pop density, age and ethnicity per zip code
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status
data.cdc.gov | Last Updated 2023-07-20T16:01:58.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
- API
Percent Of Middle School Students (grades 7-8) Who Smoke Cigarettes, New Jersey, by year: Beginning 2014
healthdata.nj.gov | Last Updated 2017-08-30T17:19:32.000ZRatio: Percentage of middle school (7th-8th grade) students who have used cigarettes on one or more days in the 30 days preceding the survey. Definition: Percentage of middle school (grades 7-8) students who have used cigarettes on one or more days in the 30 days preceding the survey. Data Source: NJDHS DMHAS NJ Middle School Risk and Protective Factor Survey History: FEB 2017 - Data source for this indicator changed to New Jersey Youth Tobacco Survey (YTS) starting with 2014 data. Previous data years were based on PRIDE survey data, New Jersey Department of Human Services. MAR 2017 - Baseline year changed from 2010 to 2014, since YTS and PRIDE data are not comparable. - 2020 targets modified to reflect a 10% improvement over the 2014 baseline for total population and all racial/ethnic groups
- API
Coronary heart disease death rates, New Jersey, by year: Beginning 2010
healthdata.nj.gov | Last Updated 2020-12-09T19:09:30.000ZRate: Age-adjusted rate of deaths due to coronary heart disease per 100,000 population. Definition: deaths with coronary heart disease as the underlying cause (ICD-10 codes: I11, I20-I25). Data Sources: (1) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health (2) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development.
- API
Deer Tick Surveillance: Adults (Oct to Dec) excluding Powassan virus: Beginning 2008
health.data.ny.gov | Last Updated 2024-05-01T18:05:44.000ZThis dataset provides the results from collecting and testing adult deer ticks, also known as blacklegged ticks, or by their scientific name <i>Ixodes scapularis</i>. Collection and testing take place across New York State (excluding New York City) from October to December, when adult deer ticks are most commonly seen. Adult deer ticks are individually tested for different bacteria and parasites, which includes the bacteria responsible for Lyme disease. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide adult tick infections at a precise location and at one point in time. Both measures, tick population density and percentage, of ticks infected with the specified bacteria or parasite can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Booster Dose
data.cdc.gov | Last Updated 2023-06-09T00:47:32.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
- API
New York State Population Data: Beginning 2003
health.data.ny.gov | Last Updated 2024-03-07T16:13:08.000ZPopulation data file is provided as an additional reference file when interpreting vital statistics death rates. The population data is derived from the corresponding release of the NCHS annual estimates of "Bridged Race Vintage" which are consistent with the Bureau of the Census estimates from "Vintage" (released in the summer). For more information, check out: http://www.health.ny.gov/statistics/vital_statistics/. The "About" tab contains additional details concerning this dataset.